[go: up one dir, main page]

ECSP22019360A - Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos - Google Patents

Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos

Info

Publication number
ECSP22019360A
ECSP22019360A ECSENADI202219360A ECDI202219360A ECSP22019360A EC SP22019360 A ECSP22019360 A EC SP22019360A EC SENADI202219360 A ECSENADI202219360 A EC SENADI202219360A EC DI202219360 A ECDI202219360 A EC DI202219360A EC SP22019360 A ECSP22019360 A EC SP22019360A
Authority
EC
Ecuador
Prior art keywords
nsd2
purinamines
piperidinil
inhibitors
methyl
Prior art date
Application number
ECSENADI202219360A
Other languages
English (en)
Inventor
Guoliang Xun
Counde Oyang
Ce Wang
Haibing Deng
Haiqiang Zeng
Jinbiao Liu
Qitao Xiao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP22019360A publication Critical patent/ECSP22019360A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona un compuesto de la Fórmula (I) (conforme gráfico constante en resumen de la memoria) o un enantiómero, una mezcla enantiomérica o una sal farmacéuticamente aceptable de este; en donde las variables son tal como se definieron en la presente. La presente invención proporciona además composiciones farmacéuticas que comprenden tales compuestos; y métodos para usar tales compuestos para tratar una enfermedad o afección mediada por la proteína nuclear 2 que contiene el dominio SET (NSD2).
ECSENADI202219360A 2019-08-14 2022-03-14 Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos ECSP22019360A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2019/100542 WO2021026803A1 (en) 2019-08-14 2019-08-14 Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
PCT/IB2020/057602 WO2021028854A1 (en) 2019-08-14 2020-08-12 Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents

Publications (1)

Publication Number Publication Date
ECSP22019360A true ECSP22019360A (es) 2022-04-29

Family

ID=72145436

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202219360A ECSP22019360A (es) 2019-08-14 2022-03-14 Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos

Country Status (20)

Country Link
US (3) US11420970B1 (es)
EP (2) EP4013755B1 (es)
JP (2) JP7638960B2 (es)
KR (1) KR20220047330A (es)
CN (1) CN114585622B (es)
AU (1) AU2020328919A1 (es)
BR (1) BR112022002520A2 (es)
CO (1) CO2022002804A2 (es)
DK (1) DK4013755T3 (es)
EC (1) ECSP22019360A (es)
ES (1) ES3023540T3 (es)
FI (1) FI4013755T3 (es)
IL (2) IL320143A (es)
MX (1) MX2022001784A (es)
MY (1) MY209614A (es)
PH (1) PH12022550343A1 (es)
PL (1) PL4013755T3 (es)
PT (1) PT4013755T (es)
WO (2) WO2021026803A1 (es)
ZA (1) ZA202200519B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021026803A1 (en) * 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
KR102779693B1 (ko) * 2019-09-20 2025-03-12 노파르티스 아게 Mll1 억제제 및 항암제
WO2023133201A1 (en) * 2022-01-05 2023-07-13 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions
EP4444305A2 (en) * 2022-02-16 2024-10-16 Duke Street Bio Limited Pharmaceutical compound
WO2023225144A1 (en) * 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225150A1 (en) * 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
CN119744262A (zh) * 2022-05-18 2025-04-01 K36治疗股份有限公司 哌啶基-甲基-嘌呤胺d-酒石酸盐、晶型，及其在治疗医学疾病和病况中的用途
US20250326752A1 (en) * 2022-05-18 2025-10-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023230038A1 (en) * 2022-05-23 2023-11-30 K36 Therapeutics, Inc. Piperidinyl-methylpurine pyrimidines and related compounds and their use in treating diseases and conditions
US20250361235A1 (en) * 2022-05-23 2025-11-27 K36 Therapeutics, Inc. Piperidinyl-methylpurine benzenes and related compounds and their use in treating diseases and conditions
EP4593836A2 (en) * 2022-09-26 2025-08-06 Board of Regents, The University of Texas System Heterocycles as modulators of nsd activity
WO2024073283A1 (en) * 2022-09-26 2024-04-04 Board Of Regents, The University Of Texas System Heterocycles as modulators of nsd activity
JP2025541228A (ja) * 2022-12-12 2025-12-18 ケイ３６・セラピューティクス・インコーポレイテッド ピペリジニル－メチル－プリンアミンを含有する医薬組成物ならびに疾患及び状態の治療におけるその使用
US20250171445A1 (en) * 2023-11-17 2025-05-29 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
CN117720550A (zh) * 2023-12-14 2024-03-19 深圳市华先医药科技有限公司 (s)-3-甲基-4-氧代-2-氧杂-8-氮杂螺[4.5]癸烷-8-甲酸叔丁酯合成方法
CN117843641B (zh) * 2023-12-28 2025-04-25 和径医药科技（上海）有限公司 Nsd3抑制剂及其制备方法和应用
WO2025147514A1 (en) * 2024-01-02 2025-07-10 K36 Therapeutics, Inc. Piperidinyl-methyl-purineamine nsd2 inhibitor therapeutic methods and compositions for treating cancer
CN118459395A (zh) * 2024-05-10 2024-08-09 南通大学 一种5-(叔丁氧羰基氨基)哌啶-3-羧酸甲酯的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386923B1 (en) 2001-04-17 2008-08-13 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine derivatives
CN1688580A (zh) * 2002-08-08 2005-10-26 记忆药物公司 作为磷酸二酯酶4抑制剂的2－三氟甲基－6－氨基嘌呤衍生物
ES2387388T3 (es) 2002-09-27 2012-09-21 Dainippon Sumitomo Pharma Co., Ltd. Compuesto de adenina y uso del mismo
JP2004137157A (ja) * 2002-10-16 2004-05-13 Sumitomo Pharmaceut Co Ltd 新規アデニン誘導体を有効成分として含有する医薬
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
NO2491035T3 (es) * 2009-10-22 2018-01-27
GB201204985D0 (en) 2012-03-21 2012-05-02 Genentech Inc Compounds
WO2019196918A1 (zh) 2018-04-13 2019-10-17 罗欣药业(上海)有限公司 五元杂环并嘧啶类化合物、药物组合物及用途
CN109223794B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物c6作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN108853110B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物a8作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
WO2021026803A1 (en) * 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
WO2023133201A1 (en) 2022-01-05 2023-07-13 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions
WO2023225144A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225150A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
US20250326752A1 (en) 2022-05-18 2025-10-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
CN119744262A (zh) 2022-05-18 2025-04-01 K36治疗股份有限公司 哌啶基-甲基-嘌呤胺d-酒石酸盐、晶型，及其在治疗医学疾病和病况中的用途

Also Published As

Publication number Publication date
FI4013755T3 (fi) 2025-04-02
EP4559915A1 (en) 2025-05-28
AU2020328919A1 (en) 2022-02-17
IL289754B1 (en) 2025-05-01
MY209614A (en) 2025-07-24
IL289754B2 (en) 2025-09-01
BR112022002520A2 (pt) 2022-05-10
EP4013755A1 (en) 2022-06-22
US20230002388A1 (en) 2023-01-05
US20250276971A1 (en) 2025-09-04
EP4013755B1 (en) 2025-01-08
JP2025081505A (ja) 2025-05-27
US11420970B1 (en) 2022-08-23
PT4013755T (pt) 2025-05-02
DK4013755T3 (da) 2025-03-31
US12312353B2 (en) 2025-05-27
WO2021026803A1 (en) 2021-02-18
WO2021028854A1 (en) 2021-02-18
JP7638960B2 (ja) 2025-03-04
CA3144542A1 (en) 2021-02-18
MX2022001784A (es) 2022-04-18
KR20220047330A (ko) 2022-04-15
CN114585622A (zh) 2022-06-03
ZA202200519B (en) 2024-08-28
IL320143A (en) 2025-06-01
IL289754A (en) 2022-03-01
PL4013755T3 (pl) 2025-05-12
ES3023540T3 (en) 2025-06-02
PH12022550343A1 (en) 2023-03-13
CO2022002804A2 (es) 2022-04-08
CN114585622B (zh) 2024-08-09
JP2022544946A (ja) 2022-10-24

Similar Documents

Publication Publication Date Title
ECSP22019360A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
CO2022010460A2 (es) Compuestos tricíclicos sustituidos
CL2019003086A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CR20220312A (es) Compuestos tricíclicos sustituidos
MX2019010539A (es) Compuestos de imidazo-piperidina fusionada que contienen una amida heterociclica de 4 miembros como inhibidores de jak.
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CL2020000283A1 (es) Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2018001193A (es) Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos.
CL2021000515A1 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
CL2020001244A1 (es) Inhibidores de inmunoproteasoma.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2024002409A (es) Terapias contra el cancer.
UY37569A (es) Inhibidores del inmunoproteasoma
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
PH12020551620A1 (en) Compositions for preventing or treating dry eye
PE20191745A1 (es) Compuestos de acido ascorbico y quinona para el tratamiento de la enfermedad de chagas